Episode Details

Up to 95% of pancreatic cancer patients have a KRAS mutation in their tumor. For decades, it was considered impossible to target with a drug. What changed?

To get the latest information, host Alisyn Camerota is joined by Dr. Eileen O'Reilly, medical oncologist and Winthrop Rockefeller Endowed Chair in Medical Oncology at Memorial Sloan Kettering Cancer Center, to unpack what RAS and KRAS actually are, why this gene resisted treatment for so long, and what the recent approval of Rasonque™ (daraxonrasib) means for patients with metastatic pancreatic cancer.

Dr. O'Reilly explains the biology behind RAS signaling, the different mutation types found in pancreatic cancer (including G12D, G12V, and G12R), how the new class of RAS-targeting drugs works, what testing for a RAS mutation involves, and what "RAS wild type" means for the small subset of patients without a detectable mutation. She also shares her perspective on what this breakthrough means for the field after years of limited progress, and where research is headed next.

PancChat is produced in collaboration with Let's Win Pancreatic Cancer and PanCAN.
PancChat is sponsored by Revolution Medicines.

Resources:

FDA Approves RASONQUE™ (daraxonrasib) - PanCAN
The FDA Approves Rasonque™ (Daraxonrasib) - Let's Win
Daraxonrasib: What To Know About Common Side Effects

Let's Win Pancreatic Cancer
Pancreatic Cancer Action Network (PanCAN)
Let's Win Clinical Trial Finder
PanCAN Clinical Trial Finder
Let's Win Doctor Finder
PanCAN Patient Services